SEARCH

SEARCH BY CITATION

References

  • 1
    American Heart Association. Heart Disease and Stroke Statistics—2008 Update (At-a-Glance Version). Dallas, Tex: American Hearth Association; 2008. Available at: http://www.americanheart.org/downloadable/heart/120007860886 2HS_Stats%202008.final.pdf. Accessed on February 11, 2009.
  • 2
    British Heart Foundation. European Cardiovascular Disease Statistics. London, United Kingdom: British Heart Foundation; 2005. Available at: www.heartstats.org. Accessed on February 11, 2009.
  • 3
    Chapman JA,Meng D,Shepherd L, et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst. 2008; 100: 252-260.
  • 4
    Jones LW,Haykowsky MJ,Swartz JJ,Douglas PS,Mackey JR. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007; 50: 1435-1441.
  • 5
    Bird BR,Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008; 14: 14-24.
  • 6
    Monnier A. Comparing AI cardiovascular safety data: trial comparators and outcomes [abstract]. Breast. 2007; 16 ( suppl. 1): S43. Abstract P109.
  • 7
    Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
  • 8
    Braithwaite RS,Chlebowski RT,Lau J,George S,Hess R,Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003; 18: 937-947.
  • 9
    McDonald CC,Alexander FE,Whyte BW,Forrest AP,Stewart HJ. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. The Scottish Cancer Trials Breast Group. BMJ. 1995; 311: 977-980.
  • 10
    Herrington DM,Klein KP. Cardiovascular trials of estrogen replacement therapy. Ann N Y Acad Sci. 2001; 949: 153-162.
  • 11
    Stamatelopoulos KS,Lekakis JP,Poulakaki NA, et al. Tamoxifen improves endothelial function and reduces carotid intima-media thickness in postmenopausal women. Am Heart J. 2004; 147: 1093-1099.
  • 12
    Hooning MJ,Dorresteijn LD,Aleman BM, et al. Decreased risk of stroke among 10-year survivors of breast cancer. J Clin Oncol. 2006; 24: 5388-5394.
  • 13
    Aiello EJ,Buist DS,Wagner EH, et al. Diffusion of AIs for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008; 107: 397-403.
  • 14
    Thurlimann B,Keshaviah A,Coates AS, et al;for the Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005; 353: 2747-2757.
  • 15
    Howell A,Cuzick J,Baum M, et al;ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 60-62.
  • 16
    Coombes RC,Kilburn LS,Snowdon CF, et al;Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007; 369: 559-570.
  • 17
    Arimidex, Tamoxifen, Alone or in Combination Trialists' Group; Buzdar A,Howell A,Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006; 7: 633-643.
  • 18
    Franklin SS,Gustin W4th,Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation. 1997; 96: 308-315.
  • 19
    Wilson PW,D'Agostino RB,Sullivan L,Parise H,Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002; 162: 1867-1872.
  • 20
    Cuppone F,Bria E,Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer. 2008; 112: 260-267.
  • 21
    Hori M,Akizuki M,Nishimura R. Comparison of adverse effects on lipid metabolism of anastrozole with tamoxifen in adjuvant setting for postmenopausal women with early breast cancer [abstract]. Eur J Cancer. 2006; 4( suppl): 94. Abstract 172.
  • 22
    Kroenke CH,Chen WY,Rosner B,Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005; 23: 1370-1378.
  • 23
    Louwman WJ,Janssen-Heijnen ML,Houterman S, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer. 2005; 41: 779-785.
  • 24
    Love RR,Wiebe DA,Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991; 115: 860-864.
  • 25
    Dewar JA,Horobin JM,Preece PE,Tavendale R,Tunstall-Pedoe H,Wood RA. Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ. 1992; 305: 225-226.
  • 26
    Saarto T,Blomqvist C,Ehnholm C,Taskinen MR,Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol. 1996; 14: 429-433.
  • 27
    McCloskey EV,Hannon RA,Lakner G, et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer. 2007; 43: 2523-2531.
  • 28
    Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group; Forbes JF,Cuzick J,Buzdar A,Howell A,Tobias JS,Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008; 9: 45-53.
  • 29
    Perez EA. The balance between risks and benefits: long-term use of aromatase inhibitors. Eur J Cancer. 2006; 4( suppl): 16-25.
  • 30
    Novartis Pharmaceuticals. Femara [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2006.
  • 31
    Coates AS,Keshaviah A,Thurlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007; 25: 486-492.
  • 32
    Mouridsen H,Keshaviah A,Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol. 2007; 25: 5715-5722.
  • 33
    Markopoulos C,Polychronis A,Zobolas V, et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat. 2005; 93: 61-66.
  • 34
    Hozumi Y,Suemasu K,Takehara M, et al. The effect of exemestane, anastrozole and tamoxifen on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of NSAS (National Surgical Adjuvant Study) BC04, the TEAM Japan sub-study [abstract]. Breast Cancer Res Treat. 2006; 100( suppl. 1): S188. Abstract 4051.
  • 35
    Geisler J,Lonning PE,Krag LE, et al. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. Eur J Cancer. 2006; 42: 2968-2975.
  • 36
    Lonning PE,Geisler J,Krag L, et al. Lipid profile and homocysteine levels in postmenopausal women with early breast cancer at low risk treated for 2 years with exemestane: follow-up results of a randomized, placebo-controlled study [abstract]. Breast Cancer Res Treat. 2005; 94( suppl. 1): S203. Abstract 4108.
  • 37
    Mamounas EP,Jeong JH,Wickerham DL, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 trial. J Clin Oncol. 2008; 26: 1965-1971.
  • 38
    Goss PE,Ingle JN,Martino S,Robert NJ,Muss HB,Piccart MJ. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005; 97: 1262-1271.
  • 39
    Wasan KM,Goss PE,Pritchard PH, et al. The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol. 2005; 16: 707-715.
  • 40
    Cigler T,Yaffe MJ,Johnston D, et al. A placebo-controlled trial examining the effects of letrozole on mammographic breast density and bone and lipid metabolism [abstract]. Breast Cancer Res Treat. 2007; 106( suppl 1): S112. Abstract 2082.
  • 41
    AstraZeneca Canada Inc. Arimidex Product Monograph. Mississauga, Ontario, Canada: AstraZeneca Canada Inc.; 2008. Available at: http://www.astrazeneca.ca/en/search/?txtTerms=arimidex. Accessed August 15, 2008.
  • 42
    Coates AS,Mouridsen H,Sun Z, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: updated safety analysis of trial BIG 1-98 [abstract]. J Clin Oncol. 2007; 25( 18 suppl):2007: 8s. Abstract 521.
  • 43
    Cuzick J,Wale C;on behalf of the ATAC Trialists' Group. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment [abstract]. Breast Cancer Res Treat. 2006; 100( suppl 1): S24. Abstract 104.
  • 44
    Mamounas EP,Lembersky B,Jeong JH, et al. NSABP B-42: a clinical trial to determine the efficacy of 5 years of letrozole compared with placebo in patients completing 5 years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer. 2006; 7: 416-421.
  • 45
    Boccardo F,Rubagotti A,Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol. 2006; 17( suppl 7): vii10-vii14.
  • 46
    Gandhi S,Verma S. Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter. Breast Cancer Res Treat. 2007; 106: 1-9.
  • 47
    Sourander L,Rajala T,Raiha I,Makinen J,Erkkola R,Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT) Lancet. 1998; 352: 1965-1969.
  • 48
    Monnier A. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial. Expert Rev Anticancer Ther. 2006; 6: 1355-1359.
  • 49
    Moy B,Elliott CR,Chapman J-AW,Pater JL,Ding Z,Goss PE. NCIC CTG MA.27: menopausal symptoms of ethnic minority women [abstract]. Breast Cancer Res Treat. 2006; 100( suppl 1): S144. Abstract 3059.
  • 50
    Rock CL,Flatt SW,Newman V, et al. Factors associated with weight gain in women after diagnosis of breast cancer. Women's Healthy Eating and Living Study Group. J Am Diet Assoc. 1999; 99: 1212-1221.
  • 51
    Irwin ML,Crumley D,McTiernan A, et al. Physical activity levels before and after a diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer. 2003; 97: 1746-1757.
  • 52
    Mahabir S,Baer DJ,Johnson LL, et al. Usefulness of body mass index as a sufficient adiposity measurement for sex hormone concentration associations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2006; 15: 2502-2507.
  • 53
    Ahn J,Schatzkin A,Lacey JVJr, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007; 167: 2091-2102.
  • 54
    Chlebowski RT,Aiello E,McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002; 20: 1128-1143.
  • 55
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497.
  • 56
    Grundy SM,Cleeman JI,Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110: 227-239.
  • 57
    Winer EP,Hudis C,Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005; 23: 619-629.